Professor Louise Emmett, MBChB, FRACP, FAANMS, MD

Professor Louise Emmett is a nuclear medicine/ theranostics specialist with a clinical research interest in prostate cancer. The advent of small molecule peptide imaging and therapy (theranostics) is changing the face of oncology diagnosis, prognosis, and treatment. This has had a dramatic impact in prostate cancer, with a paradigm shift in clinical practice. At the forefront of this shift in clinical practice, Prof Emmett has commenced and contributed to multiple imaging and therapy trials in prostate cancer using PSMA PET and PSMA targeted therapy between 2014 and 2024. This has involved being principal investigator (or Co-PI) on multiple prospective phase 1-3 imaging (PROPS, PRIMARY, PRIMARY2, PROPELLER) and therapy trials (LUPIN, AcTION, ENZA-P, EVOLUTION); in addition to being a member on steering committees and site principal investigator of many more trials. Prof Emmett is focused on the development of new theranostic agents, optimal combinations and functional imaging biomarkers for better personalization of treatment choices in prostate cancer theranostics. Director Theranostics and Nuclear Medicine, St Vincent’s Hospital Sydney Australia Clinical Research Leader, Garvan Institute of Medical Research, Sydney, Australia. Conjoint Professor of Medicine, University of New South Wales, Sydney Australia